The stock was trading down more than 5.5% at the time of writing following the revelation that in the REDEFINE 2 trial, CagriSema (cagrilintide and semaglutide) achieved a weight loss of 15.7% ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

It has other candidates in its late-stage obesity pipeline, headed by CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide with semaglutide. Phase 3 results reported ...

which combines cagrilintide with its signature semaglutide — the active ingredient in Wegovy. Zealand's CEO Adam Steensberg told CNBC in October that it expects to bring petrelintide to market ...

People were randomly assigned to receive either CagriSema, a fixed-dose combination of cagrilintide 2.4 milligram and semaglutide 2.4 milligram or placebo. The mean baseline body weight was 102.2 ...